Show simple item record

dc.contributor.authorFasullo, Matthew J.
dc.contributor.authorRau, Prashanth
dc.contributor.authorLiu, Dong-Qi
dc.contributor.authorHolzwanger, Erik
dc.contributor.authorMathew, Jomol
dc.contributor.authorGuilarte-Walker, Yurima
dc.contributor.authorSzabo, Gyongyi
dc.date2022-08-11T08:09:53.000
dc.date.accessioned2022-08-23T16:47:37Z
dc.date.available2022-08-23T16:47:37Z
dc.date.issued2019-06-27
dc.date.submitted2019-08-05
dc.identifier.citation<p>World J Hepatol. 2019 Jun 27;11(6):522-530. doi: 10.4254/wjh.v11.i6.522. <a href="https://doi.org/10.4254/wjh.v11.i6.522">Link to article on publisher's site</a></p>
dc.identifier.issn1948-5182 (Print)
dc.identifier.doi10.4254/wjh.v11.i6.522
dc.identifier.pmid31293720
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41116
dc.description.abstractBACKGROUND: Liver cirrhosis is the late stage of hepatic fibrosis and is characterized by portal hypertension that can clinically lead to decompensation in the form of ascites, esophageal/gastric varices or encephalopathy. The most common sequelae associated with liver cirrhosis are neurologic and neuropsychiatric impairments labeled as hepatic encephalopathy (HE). Well established triggers for HE include infection, gastrointestinal bleeding, constipation, and medications. Alterations to the gut microbiome is one of the leading ammonia producers in the body, and therefore may make patients more susceptible to HE. AIM: To investigate the relationship between the use of proton pump inhibitors (PPIs) and HE in patients with cirrhosis. METHODS: This is a single center, retrospective analysis. Patients were included in the study with an admitting diagnosis of HE. The degree of HE was determined from subjective and objective portions of hospital admission notes using the West Haven Criteria. The primary outcome of the study was to evaluate the grade of HE in PPI users versus non-users at admission to the hospital and throughout their hospital course. Secondary outcomes included rate of infection, gastrointestinal bleeding within the last 12 mo, mean ammonia level, and model for end-stage liver disease scores at admission. RESULTS: The HE grade at admission using the West Haven Criteria was 2.3 in the PPI group compared to 1.7 in the PPI nonuser group (P = 0.001). The average length of hospital stay in PPI group was 8.3 d compared to 6.5 d in PPI nonusers (P = 0.046). Twenty-seven (31.8%) patients in the PPI user group required an Intensive Care Unit admission during their hospital course compared to 6 in the PPI nonuser group (16.7%) (P = 0.138). Finally, 10 (11.8%) patients in the PPI group expired during their hospital stay compared to 1 in the PPI nonuser group (2.8%) (P = 0.220). CONCLUSION: Chronic PPI use in cirrhotic patients is associated with significantly higher average West Haven Criteria for HE compared to patients that do not use PPIs.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=31293720&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright ©The Author(s) 2019. This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectCirrhosis
dc.subjectHepatic encephalopathy
dc.subjectHepatology
dc.subjectProton pump inhibitor
dc.subjectProton pump inhibitors
dc.subjectChemical Actions and Uses
dc.subjectDigestive System Diseases
dc.subjectHepatology
dc.subjectPathological Conditions, Signs and Symptoms
dc.subjectTherapeutics
dc.titleProton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients
dc.typeJournal Article
dc.source.journaltitleWorld journal of hepatology
dc.source.volume11
dc.source.issue6
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4920&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3904
dc.identifier.contextkey15059849
refterms.dateFOA2022-08-23T16:47:37Z
html.description.abstract<p>BACKGROUND: Liver cirrhosis is the late stage of hepatic fibrosis and is characterized by portal hypertension that can clinically lead to decompensation in the form of ascites, esophageal/gastric varices or encephalopathy. The most common sequelae associated with liver cirrhosis are neurologic and neuropsychiatric impairments labeled as hepatic encephalopathy (HE). Well established triggers for HE include infection, gastrointestinal bleeding, constipation, and medications. Alterations to the gut microbiome is one of the leading ammonia producers in the body, and therefore may make patients more susceptible to HE.</p> <p>AIM: To investigate the relationship between the use of proton pump inhibitors (PPIs) and HE in patients with cirrhosis.</p> <p>METHODS: This is a single center, retrospective analysis. Patients were included in the study with an admitting diagnosis of HE. The degree of HE was determined from subjective and objective portions of hospital admission notes using the West Haven Criteria. The primary outcome of the study was to evaluate the grade of HE in PPI users versus non-users at admission to the hospital and throughout their hospital course. Secondary outcomes included rate of infection, gastrointestinal bleeding within the last 12 mo, mean ammonia level, and model for end-stage liver disease scores at admission.</p> <p>RESULTS: The HE grade at admission using the West Haven Criteria was 2.3 in the PPI group compared to 1.7 in the PPI nonuser group (P = 0.001). The average length of hospital stay in PPI group was 8.3 d compared to 6.5 d in PPI nonusers (P = 0.046). Twenty-seven (31.8%) patients in the PPI user group required an Intensive Care Unit admission during their hospital course compared to 6 in the PPI nonuser group (16.7%) (P = 0.138). Finally, 10 (11.8%) patients in the PPI group expired during their hospital stay compared to 1 in the PPI nonuser group (2.8%) (P = 0.220).</p> <p>CONCLUSION: Chronic PPI use in cirrhotic patients is associated with significantly higher average West Haven Criteria for HE compared to patients that do not use PPIs.</p>
dc.identifier.submissionpathoapubs/3904
dc.contributor.departmentInformation Technology, Department of Data Sciences and Technology
dc.contributor.departmentDepartment of Population and Quantitative Health Sciences
dc.contributor.departmentDepartment of Medicine, Division of Gastroenterology
dc.source.pages522-530


Files in this item

Thumbnail
Name:
WJH_11_522.pdf
Size:
664.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright ©The Author(s) 2019. This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Except where otherwise noted, this item's license is described as Copyright ©The Author(s) 2019. This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/